Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Schamim H. Eckert"'
Autor:
Maximilian Pohland, Maren Pellowska, Heike Asseburg, Stephanie Hagl, Martina Reutzel, Aljoscha Joppe, Dirk Berressem, Schamim H. Eckert, Mario Wurglics, Manfred Schubert‐Zsilavecz, Gunter P. Eckert
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-12 (2018)
Abstract Background Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated receptor gamma (P
Externí odkaz:
https://doaj.org/article/d3adf72618f74d0eb45cc6102776126a
Autor:
Walter E. Müller, Schamim H. Eckert, Kristina Friedland, Carola Stockburger, Gunter P. Eckert
Publikováno v:
Journal of Alzheimer's Disease. 64:S455-S467
Because of the failure of all amyloid-β directed treatment strategies for Alzheimer's disease (AD), the concept of mitochondrial dysfunction as a major pathomechanism of the cognitive decline in aging and AD has received substantial support. Accordi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9a435523263326b0b0b2c01718d63d
https://doi.org/10.3233/jad-179915
https://doi.org/10.3233/jad-179915
Autor:
Schamim H. Eckert, Walter E. Müller, Janett Eckmann, Kristina Friedland, Stephanie Hagl, Gunter P. Eckert
Publikováno v:
Experimental neurology. 329
Background Approved drugs for Alzheimer's disease (AD) only have a symptomatic effects and do not intervene causally in the course of the disease. Olesoxime (TRO19622) has been tested in AD disease models characterized by improved amyloid precursor p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575026f2632c88d58a169a90428a9ef5
https://pubmed.ncbi.nlm.nih.gov/32199815
https://pubmed.ncbi.nlm.nih.gov/32199815
Autor:
Maximilian, Pohland, Maren, Pellowska, Heike, Asseburg, Stephanie, Hagl, Martina, Reutzel, Aljoscha, Joppe, Dirk, Berressem, Schamim H, Eckert, Mario, Wurglics, Manfred, Schubert-Zsilavecz, Gunter P, Eckert
Publikováno v:
Alzheimer's Research & Therapy
Background Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated receptor gamma (PPARγ) mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7741f0f5d2a485af24c56d4a346d26a3
https://pubmed.ncbi.nlm.nih.gov/29433569
https://pubmed.ncbi.nlm.nih.gov/29433569
Autor:
Janett Eckmann, Kristina Leuner, Schamim H. Eckert, Kathrin Renner, Walter E. Müller, Gunter P. Eckert
Publikováno v:
Journal of Alzheimer's Disease. 31:21-32
Due to their role in producing energy, as major sources of free radicals, and as critical regulators of apoptosis, mitochondria play a dominant role in the central nervous system (CNS). Mitochondrial dysfunction represents one major pathomechanism of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69b244136a6df43b407e7d41a696cbd
https://doi.org/10.3233/jad-2012-120310
https://doi.org/10.3233/jad-2012-120310
Autor:
Gunter P. Eckert, Kathrin Renner, Schamim H. Eckert, Walter E. Müller, Stephanie Hagl, Janett Eckmann, Kristina Leuner, Christopher Kurz, Reham M. Abdel-Kader
Publikováno v:
Molecular Neurobiology. 46:136-150
Increasing evidences suggest that mitochondrial dysfunction plays an important role in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD). Alterations of mitochondrial efficiency and function are mainly related to alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f529beac70129f8d346d04ca92d84f52
https://doi.org/10.1007/s12035-012-8271-z
https://doi.org/10.1007/s12035-012-8271-z
Autor:
Kristina Friedland, Janett Gaca, Walter E. Müller, Nathalie Kolesova, Schamim H. Eckert, Gunter P. Eckert
Publikováno v:
Aging and Disease
Dimebon (latrepirdine), an old antihistaminic drug, showed divergent results in two large clinical trials in Alzheimer disease (AD), which according to our review might be related to the specific pharmacological properties of the drug and the differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f181001d4d383704d488f9567e91b3
https://doi.org/10.14336/ad.2017.1014
https://doi.org/10.14336/ad.2017.1014
Autor:
Gunter P. Eckert, LE Clemens, Jonasz J. Weber, Carsten Calaminus, Andreas Weiss, E Jansson, Libo Yu-Taeger, Tanja T. Wlodkowski, Thierry Bordet, Rebecca M. Pruss, Olaf Riess, Bernd J. Pichler, Janett Gaca, Janine Magg, Huu P. Nguyen, Schamim H. Eckert, Magali Michaud
Publikováno v:
Brain : a journal of neurology. 138(Pt 12)
Huntington's disease is a fatal human neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene, which translates into a mutant huntingtin protein. A key event in the molecular pathogenesis of Huntington's disease is the proteolytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8057726c5a179b073feba090d55ce6fd
https://pubmed.ncbi.nlm.nih.gov/26490331
https://pubmed.ncbi.nlm.nih.gov/26490331
Autor:
Stephanie Hagl, LE Clemens, Walter E. Müller, Janett Eckmann, Rebecca M. Pruss, Kristina Leuner, Gunter P. Eckert, Huu P. Nguyen, Thierry Bordet, Schamim H. Eckert, Libo Yu-Taeger
Publikováno v:
Molecular neurobiology. 50(1)
Huntington disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin gene (HTT). One prominent target of the mutant huntingtin protein (mhtt) is the mitochondrion, affecting its morphology, distri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14795986680eb2bc8d159a8f3109223d
https://pubmed.ncbi.nlm.nih.gov/24633813
https://pubmed.ncbi.nlm.nih.gov/24633813
Autor:
Carola Stockburger, Konrad Koch, Walter E. Müller, Schamim H. Eckert, Kristina Leuner, Christopher Kurz
Publikováno v:
Biochemical Society transactions. 41(5)
The metabolic enhancer piracetam is used in many countries to treat cognitive impairment in aging, brain injuries, as well as dementia such as AD (Alzheimer's disease). As a specific feature of piracetam, beneficial effects are usually associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eff171fb9ad1b47596eb4b4abe0938a
https://pubmed.ncbi.nlm.nih.gov/24059528
https://pubmed.ncbi.nlm.nih.gov/24059528